Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections

NCT: NCT07610967 · NOT_YET_RECRUITING

NCT IDNCT07610967
StatusNOT_YET_RECRUITING
Start Date2026-06
Completion2028-06

Brief Summary

The purpose of trial is to determine if daily usage of a photobiomodulation device will decrease the incidence of upper respiratory tract infections (URI) due to COVID, influenza or other viruses.The RD-X10 device is handheld, can be self-administered, and has been shown to be safe in invivo studies.

Frequently Asked Questions

What is Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections?

Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections is a clinical trial registered under NCT07610967. Current status: NOT_YET_RECRUITING.

What is the status of NCT07610967?

The current status of NCT07610967 (Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections) is: NOT_YET_RECRUITING.

When did Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections start?

Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections started on 2026-06.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑